HR+/HER2-

Adela-Luciana Oprea1, Bahadir Gulluoglu2, Yusuf Emre Aytin3

  • 1Department of Obstetrics and Gynecology 2, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureș, Romania.

PubMed
概括

玛吉方程3 (MagEq3) 和IHC4评分,以及HER2低状态,可以帮助预测激素受体阳性,HER2阴性乳腺癌患者对新辅助化疗 (NAC) 的满意反应.